Janus Henderson Group
LENZ

Janus Henderson Group’s LENZ Therapeutics LENZ Stock Holding History

Janus Henderson Group’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,900
Closed -$229K – 2485
2025
Q3 		$229K Buy
+4,900
New +$180K ﹤0.01% 2297
2022
Q2 		– Sell
-75,190
Closed -$2.68M – 2701
2022
Q1 		$2.68M Buy
+75,190
New +$4.7M ﹤0.01% 1150
2021
Q4 		– Sell
-136,868
Closed -$15.2M – 2595
2021
Q3 		$15.2M Sell
136,868
-41,847
-23% -$6.2M 0.01% 843
2021
Q2 		$36.7M Buy
+178,715
New +$31.1M 0.02% 648

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Janus Henderson Group's LENZ Position: Q4 2025 in Review

Janus Henderson Group sold out of LENZ Therapeutics (LENZ) in Q4 2025, closing a stake of 4,900 shares — an estimated $229K sold.

Janus Henderson Group first reported a position in LENZ in Q2 2021 and held it in 4 quarters. The position peaked at $36.7M in Q2 2021. 160 funds tracked by Wall St. Rank hold LENZ as of Q4 2025.

  • Janus Henderson Group reported no remaining LENZ Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Janus Henderson Group sold 4,900 LENZ Therapeutics shares in Q4 2025, an estimated $229K.
  • Janus Henderson Group first reported a position in LENZ Therapeutics in Q2 2021 and held it in 4 quarters.
  • Janus Henderson Group's LENZ Therapeutics position peaked at $36.7M in Q2 2021.
  • 160 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2025.

Based on Janus Henderson Group's 13F filing for Q4 2025, filed 17 Feb 2026.